Zentalis Pharmaceuticals Inc. (ZNTL)
NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:52 AM ET
ZNTL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $243.83M
- EPS (TTM)
- -$1.96
- Dividend yield
- None
- 52-week range
- 1.21 – 6.95
- Day range
- 2.45 – 2.51
- Volume / Avg
- 56.15K / 1.20M
- Beta
- —
- Shares outstanding
- 98.12M
- Next earnings
- Nov 10, 2026
52-week range
ZNTL stock today
Shares of Zentalis Pharmaceuticals (ZNTL) are trading lower on Oct 8 at $2.49, a drop of 2.55% or $0.065 per share, versus the S&P 500's 0.25% decline. At this level, ZNTL sits in the middle of its 52-week range of $1.21 to $6.95: 64.2% below the high, set on Apr 10, 2026 and 105.0% above the low. ZNTL is up 88.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 64.5%.
Zentalis Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.96), so its P/E ratio is not meaningful. Zentalis Pharmaceuticals's next earnings report is expected on Nov 10, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Zentalis Pharmaceuticals
Company profileZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Julie M. Eastland M.B.A.
- Headquarters
- San Diego, CA
- Employees
- 106
- IPO year
- 2020
- Website
- zentalis.com
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$7.33+194.97%
- Strong buy 0
- Buy 6
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 10, 2026
Zentalis Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMRNAmarin Corporation plc | 11.96 | -0.50% | $252.63M | vs ZNTL |
| ACIUAC Immune SA | 2.55 | -0.78% | $253.54M | vs ZNTL |
| BCYCBicycle Therapeutics plc ADR | 3.68 | -1.34% | $257.57M | vs ZNTL |
| VCREVicore Pharma Holding AB ADR | 8.76 | +1.15% | $246.72M | vs ZNTL |
| UPBUpstream Bio Inc. | 4.48 | -2.84% | $245.37M | vs ZNTL |
| LFCRLifecore Biomedical Inc. | 6.45 | +0.08% | $244.30M | vs ZNTL |
| IMRXImmuneering Corporation Class A | 3.75 | -2.85% | $242.62M | vs ZNTL |
| AKBAAkebia Therapeutics Inc. | 0.8535 | -2.27% | $236.51M | vs ZNTL |
Indexes, lists and sector
Zentalis Pharmaceuticals stock FAQ
What is Zentalis Pharmaceuticals's stock price today?
ZNTL last traded at $2.49 as of Oct 8, 9:52 AM EDT, down 2.55% on the day. Prices are delayed at least 15 minutes.
When is Zentalis Pharmaceuticals's next earnings date?
Zentalis Pharmaceuticals is expected to report earnings on Tuesday, November 10, 2026.
Who is Zentalis Pharmaceuticals's CEO?
Ms. Julie M. Eastland M.B.A. is the chief executive officer of Zentalis Pharmaceuticals Inc., which has about 106 employees.
What is the ZNTL 52-week high?
The 52-week high for ZNTL is $6.95 and the 52-week low is $1.21. The stock is currently 64.2% below its high.